“There are many, many other factors that need to come into play. And perhaps the foremost among them is the importance of transferring know how to new production sites. It’s not enough to have the recipe for making these vaccines, you need to have the know how, as well that means, trained, skilled workers. It means having the right equipment. It also means having a regulatory infrastructure that is both strict and transparent.”... it’s important that we look closely at export restrictions and prohibitions, and bureaucratic procedures customs procedures, red tape that has slowed the trade in vaccines diagnostics and therapeutics,” Rockwell said, reporting on Iweala’s remarks.
Referring back to a high-level meeting with pharma companies last month, he noted that they had stressed that one of the biggest obstacles to ramping up production was access to raw inputs and materials:..."
healthpolicy-watch.news/...h-towards-text-based-negotiations/
Zurück
Weiter
